Shares of vaccine maker Moderna Inc. fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product revenue guidance in six months. Moderna shares fell 2% in ...

In a report released on February 14, Luca Issi from RBC Capital maintained a Hold rating on Moderna (MRNA – Research Report), with a price ...

Pharmaceutical giant Moderna Inc. (NASDAQ:MRNA) lost 7.28 percent of its value on Monday to end the day at $36.55 apiece as investors continued to sell off positions following Goldman Sachs ...

EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...

Expectations of a banner year in dealmaking have not yet materialized due to worries about inflation and uncertainties over U ...

Click here for access. * Consistent in their evaluation, an analyst from Goldman Sachs keeps a Buy rating on Moderna with a target price of $99. * An analyst from UBS persists with their Buy ...

Investors seeking to outperform the market should focus their stock-picking efforts on volatile names in the consumer discretionary, information technology and communications services industries, ...

Moderna Inc. recorded another quarterly loss as vaccine sales wane and the company had an unexpected charge for canceled ...